CymaBay Therapeutics, Inc. (CBAY) NASDAQ

32.48

+0.01(+0.03%)

Updated at March 21, 2024 04:00PM

Currency In USD

CymaBay Therapeutics, Inc.

Address

7575 Gateway Boulevard

Newark, CA 94560

United States of America

Phone

510 293 8800

Sector

Healthcare

Industry

Biotechnology

Employees

101

First IPO Date

February 03, 2014

Key Executives

NameTitlePayYear Born
Mr. Sujal A. ShahPresident, Chief Executive Officer & Director1.04M1973
Ms. Klara A. Dickinson-EasonChief Regulatory & Quality Assurance Officer441,8361968
Mr. Paul T. QuinlanGeneral Counsel, Chief Compliance Officer & Corporate Secretary629,7201963
Dr. Charles A. McWherter Ph.D.President of Research & Development and Chief Scientific Officer700,6481955
Dr. Robert L. MartinSenior Vice President of Manufacturing & Nonclinical Development01962
Ms. Becki FiliceSenior Vice President of Portfolio & Product Leadership01961
Mr. Patrick J. O'MaraSenior Vice President of Business Development01961
Mr. Ben KozubHead of Commercial0N/A
Mr. Harish Shantharam C.F.A.Chief Financial Officer, Principal Accounting & Financial Officer01982
Mr. Ken BoehmSenior Vice President of Human Resources0N/A

Description

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.